Evaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations

The rising global prevalence of obesity and its associated health problems necessitate effective intervention strategies. Historically, many anti-obesity medications have been developed and later withdrawn because of unfavorable adverse event profiles. By contrast, recently introduced glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) demonstrate remarkable efficacy for weight loss. Furthermore, they confer beneficial effects on cardiovascular and renal outcomes and metabolic dysfunction-associated liver disease. Despite these benefits, adverse events such as retained gastric content and pulmonary aspiration remain a concern. Consequently, this review summarizes current evidence and offers clinical guidance on GLP-1 RA-related adverse effects.